Viral and Symptom Rebound Following Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Monoclonal Antibody Therapy in a Randomized Placebo-Controlled Trial.
Saved in:
| Title: | Viral and Symptom Rebound Following Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Monoclonal Antibody Therapy in a Randomized Placebo-Controlled Trial. |
|---|---|
| Authors: | Chew KW; Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA., McGinley B; Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts, USA., Moser C; Center for Biostatistics in AIDS Research, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA., Li JZ; Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA., Evering TH; Department of Medicine, Weill Cornell Medicine, New York, New York, USA., Ritz J; Center for Biostatistics in AIDS Research, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA., Javan AC; Division of AIDS/National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland, USA., Margolis D; Brii Biosciences, Durham, North Carolina, USA., Wohl DA; Department of Medicine, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, USA., Hughes MD; Center for Biostatistics in AIDS Research, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA., Daar ES; Lundquist Institute at Harbor-UCLA Medical Center, Torrance, California, USA., Currier JS; Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA., Eron JJ; Department of Medicine, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, USA., Smith DM; Department of Medicine, University of California, San Diego, La Jolla, California, USA. |
| Corporate Authors: | Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV)-2/A5401 Study Team, Study Sites, and Investigators |
| Source: | The Journal of infectious diseases [J Infect Dis] 2025 Feb 04; Vol. 231 (1), pp. 131-136. |
| Publication Type: | Clinical Trial, Phase II; Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial |
| Journal Info: | Publisher: Oxford University Press Country of Publication: United States NLM ID: 0413675 Publication Model: Print Cited Medium: Internet ISSN: 1537-6613 (Electronic) Linking ISSN: 00221899 NLM ISO Abbreviation: J Infect Dis Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1537-6613 |
|---|---|
| DOI: | 10.1093/infdis/jiae501 |
